Ilya Rachman, MD PhD
lya Rachman is the Chief Executive Officer of Immix Biopharma, Inc. Dr. Rachman is a physician/scientist and former clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson.
Ilya founded a Clinical Research organization that conducted clinical trials of pharmaceutical drugs, and completed several clinical trials as a Principal Investigator building strong relationships in the clinical research industry.
Gabriel Morris,, BA
Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC, a life sciences advisory and investment firm based in San Francisco, since founding. Prior, Mr. Morris was the interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company, where he completed a growth […]
Michael Grabow
Michael is the Chief Commercial Officer of Immix Biopharma, Inc. Michael has more than 25 years of biopharmaceutical commercialization experience. Prior to joining Immix, Michael was Head of Commercial Operations at Chimerix, Inc., where he led Go-To-Market Strategy and Launch of orphan drug MODEYSO® (dordaviprone), a first-in-disease therapy that was granted accelerated approval in 2025 […]
David Marks, MBBS, PhD
Dr. Marks is the Chief Medical Officer at Immix Biopharma. Prior to Immix, Dr. Marks has held positions of increasing responsibility and most recently been the Director and Lead Clinician at Bristol Allogenic Adult Bone Marrow Transplant Unit and a Professor in Hematology and Stem Cell Transplantation in the Department of Molecular and Cellular Medicine, […]
David He, MD PhD
David He is Head of Technical Operations at Immix biopharma, Inc. David possesses more than 17 years of experience with roles spanning Legend Biotech and Boehringer Ingelheim. His expertise includes process development, technology transfer, clinical and commercial manufacturing, and regulatory filings. David holds an MD and PhD in Immunology.
Denise Bruns, PHD
